Feedback / Questions
litifilimab (BIIB059) - Biogen
Litifilimab: Regulatory submission in US for SLE/CLE in 2027
(Royalty Pharma)
-
Jun 1, 2026 -
Q1 2026 Results
FDA filing
•
Cutaneous Lupus Erythematosus • Lupus • Systemic Lupus Erythematosus
https://www.royaltypharma.com/wp-content/uploads/2026/05/Q1-2026-presentation-vFINAL.pdf
Jun 1, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious